Clinical Trial Search

Primary: Anti-HI Antibody Titers Against 4 Strains of Influenza Disease — 29.8; 14.9; 13.1; 13.5 Titers

Primary: Sum of Pain Intensity Difference (SPID) Over 48 Hours — 50.8; 168.4; 194.9 units on a scale — p=0.006

Primary: Fasting Insulin — 10.26; 10.39 uIU/ml

Primary: Percentage of Participants With Sustained Accumulation of Disability (SAD) — 21.13; 12.71 percentage of participants — p=0.0084

Primary: Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo, — -56.0; -96.3; -91.3; -85.9 minutes

Primary: Overall Survival (5-year Rate Reported) — 84.9; 87.2 percentage of participants — p=0.81

Primary: Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20 Response) at Week 24 — 86 percentage of participants

Primary: Incidence Rate of New Digital Ulcers (DUs) up to Week 16 — 0.9082; 0.9567; 0.8115 number of new DUs/observation days — p=0.706

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses — 97.0; 90.2 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate — 99.5…

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment — 91.8; 96.5 Percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 96.4 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses — 97.7; 100 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 96.3 percentage of participants

Primary: Progression-Free Survival (PFS) Based on IRR — 10.9; 7.0 months — p=<0.0001